Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
NCT ID NCT06673693
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This phase II trial is exploring whether combining stereotactic body radiation therapy (SBRT) with the immunotherapy drug tislelizumab, given before surgery, can help people with locally advanced head and neck squamous cell carcinoma. The study will enroll about 24 adults aged 18 to 70 with resectable tumors. The main goal is to see how many patients have a major pathological response—meaning few surviving tumor cells remain after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (an immunotherapy drug) combined with stereotactic body radiation therapy (SBRT)
- What this could lead to
- If successful, this approach could shrink tumors before surgery, potentially improving outcomes for people with advanced head and neck cancer.
- What could go wrong
- This is a small, early-phase study, so results may not apply broadly. The combination may cause side effects or may not improve surgical outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy combo shrink head and neck tumors before surgery?
- Can a glowing drug light up head and neck tumors?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Vaccine trains immune system to fight HPV-Positive head and neck tumors
- New drug combo aims to shrink oral cancers before surgery
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors